We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Molecular Devices

Molecular Devices provides innovative bioanalytical solutions for protein and cell biology in life science research, ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Regulatory T Cells in Leprosy Maintain Anti-Inflammatory Function

By LabMedica International staff writers
Posted on 10 Aug 2022
Print article
Image: The SpectraMax plus microplate reader was used to show that regulatory T cells in erythema nodosum leprosum maintain anti-inflammatory function (Photo courtesy of Molecular Devices)
Image: The SpectraMax plus microplate reader was used to show that regulatory T cells in erythema nodosum leprosum maintain anti-inflammatory function (Photo courtesy of Molecular Devices)

Leprosy is caused by Mycobacterium leprae, an intracellular acid-fast bacillus and is complicated by episodes of inflammation called leprosy reactions. Leprosy reactions are important causes of nerve damage and illness.

Erythema Nodosum Leprosum (ENL), also called type 2 reaction, is a severe systemic immune-mediated complication of borderline and lepromatous leprosy. ENL causes high morbidity and thus requires immediate medical attention. The numbers of circulating regulatory T cells (Tregs) are increased in lepromatous leprosy (LL) but reduced in ENL, the inflammatory complication of LL.

Clinical Scientists at the London School of Hygiene and Tropical Medicine (London, UK) working with their colleagues at the Armauer Hansen Research Institute (Addis Ababa, Ethiopia) recruited 60 untreated patients with lepromatous leprosy (30 patients with ENL reactions and 30 patients without ENL reactions) in Ethiopia to better understand the loss of immune regulation in ENL. They took blood samples at two time points before and after prednisolone treatment and assessed if the regulatory T-cells in these patients are functionally competent to control inflammation.

Frozen peripheral blood mononuclear cells (PBMC) were thawed, washed and incubated with 20μL of CD25 micro beads II, processed and added to a MS column attached to a Magnetic Cell Sorter (MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany). Lymphocyte stimulation tests (LST) were performed. Supernatants were analyzed for cytokines using a Ready-Set-Go sandwich ELISA. Capture and biotinylated detection antibodies directed against IFN-γ, TNFα and IL-10 (Thermo Fisher Scientific, Altrincham, UK) were used employing 96-well flat-bottom polystyrene MaxiSorp ELISA plates. For all plates, the optical density (OD) at 450 nm was measured using a SpectraMax plus microplate reader (Molecular Devices, Wokingham, UK).

The investigators reported that the depletion of CD25+ cells from PBMCs was associated with enhanced TNFα and IFNγ responses to M. leprae stimulation before and after 24 weeks treatment of LL with multidrug therapy (MDT) and of ENL with prednisolone. The addition of autologous CD25+ cells to CD25+ depleted PBMCs abolished these responses. In both non-reactional LL and ENL groups mitogen (PHA)-induced TNFα and IFNγ responses were not affected by depletion of CD25+ cells either before or after treatment. Depleting CD25+ cells did not affect the IL-10 response to M. leprae before and after 24 weeks of MDT in participants with LL.

The depletion of CD25+ cells was associated with an enhanced IL-10 response on stimulation with M. leprae in untreated participants with ENL and reduced IL-10 responses in treated individuals with ENL. The enhanced IL-10 in untreated ENL and the reduced IL-10 response in prednisolone treated individuals with ENL were abolished by addition of autologous CD25+ cells.

The authors concluded that their findings confirmed that T cell unresponsiveness in LL is M. leprae antigen specific and can be reversed after treatment of LL with MDT or by depleting Tregs. The study has shown that Tregs cells do not affect the IL-10 response to M. leprae in individuals with LL. They have also shown that the suppressive function of Tregs in ENL is very likely intact. The pathogenesis of ENL is apparently associated with decreased number of Tregs, but not with loss of function. The study was published on July 22, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
London School of Hygiene and Tropical Medicine 
Armauer Hansen Research Institute 
Miltenyi Biotec
Thermo Fisher Scientific
Molecular Devices 

Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
New
Real-Time Fluorescent Quantitative PCR System
AccuRa-32
New
Automated Hematology Workstation
XN-3000

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.